Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
DRUG: Fluticasone Propionate 250mcg / salmeterol 50mcg
DRUG: Double-dummy placebo
DRUG: Salbutamol as needed

Sponsor

GlaxoSmithKline